A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB)
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2019
Price : $35 *
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms EUCLIDS
- 14 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 17 Oct 2018 Status changed from active, no longer recruiting to completed.
- 15 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.